Erasca stock reports a second quarter loss after August results
Published on 10/01/2026 at 05:38 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Erasca stock was shown at USD 14.66 on Nasdaq on October 1, 2026, against a USD 14.21 prior close. The clinical-stage biotechnology company reported a second-quarter loss of USD 0.14 per share, missing the USD 0.11 consensus estimate by USD 0.03, according to MarketBeat on September 24, 2026.
Quarterly loss sets the baseline
The USD 0.14 adjusted? no. The reported second-quarter earnings per share figure came after Erasca announced its results on August 11, 2026. The same report placed the consensus loss at USD 0.11, creating a USD 0.03 per-share shortfall that gives investors a clear measure of execution against expectations.
Erasca's second-quarter net loss was USD 44.08 million, while operating cash flow was negative USD 27.27 million for the period ended June 30, 2026. Cash and cash equivalents stood at USD 42.54 million on June 30, 2026, according to the structured financial statement data for ERAS.
Analyst targets remain higher
MarketBeat reported a Moderate Buy consensus on September 24, 2026, based on eight Buy ratings, two Holds and one Sell rating, with an average price target of USD 22.09. The target level gives the analyst view a concrete benchmark against the USD 14.66 Nasdaq quote shown on October 1, 2026.
Recent research cited by Investing.com included a USD 33.00 target from JPMorgan on August 27, 2026, a USD 30.00 target from Stifel on August 17, 2026, and a USD 21.00 target from Guggenheim on August 13, 2026. The range shows how valuation depends on expectations for Erasca's clinical pipeline rather than current product revenue.
Pipeline funding remains central
On July 13, 2026, Erasca announced an upsized offering of 31,428,572 shares at USD 17.50 per share, according to Erasca. The company said the proceeds would support research and development and working capital, making financing and potential dilution important counterweights to the analyst optimism.
Yahoo Finance reported on September 4, 2026 that the FDA granted Fast Track Designation to ERAS-0015 for metastatic pancreatic adenocarcinoma. That regulatory milestone adds a clinical development catalyst, while the second-quarter loss underscores the cost of advancing several programs.
Erasca stock has a dated earnings marker
Erasca was shown at USD 14.66 on Nasdaq on October 1, 2026, with a USD 2.11 to USD 24.28 52-week range and a market capitalization of USD 5.1 billion. Investing.com lists November 11, 2026 as the next earnings date, giving the market a defined checkpoint for cash use, pipeline progress and updated guidance.
Erasca stock facts
- Company: Erasca, Inc.
- Ticker: ERAS
- Primary exchange: Nasdaq
- Price Nasdaq as of October 1, 2026: USD 14.66
- Prior close Nasdaq: USD 14.21
- Market capitalization: USD 5.1 billion (as of October 1, 2026)
- 52-week range: USD 2.11-24.28
- Sector / Industry: Healthcare / Biotechnology
- Next earnings date: November 11, 2026
